1.0
2. Juni 2010
Mitarbeiter (anonym)
Aktueller Mitarbeiter
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
the things that are left are still valuable (but doubtless outsourced soon) it's not as bad as other pharma atm you can still get science done if you try
Kontras
everything is done to a cost, regardless, and you get what you pay for people are waiting for a payout success in spite of not because of